Kyverna's miv-cel Shows Two-Year Disability Benefit in Progressive MS
KYTX is trading near its 52-week low of $5.4 (0.6% above the low) on light trading volume (0.3× avg).
Summary
Kyverna presented updated Phase 1 investigator-initiated data at MS Toronto 2026 showing all five evaluable progressive MS patients had stable or improved EDSS scores, with four of five holding benefit past one year and the first patient treated sustaining benefit beyond two years. The safety profile held up: no high-grade CRS and no ICANS or IEC-HS across six treated patients. Biological activity was clean — CAR T cells reached cerebrospinal fluid, CD19+ B cells were fully depleted, and naive B cells repopulated from month three, consistent with an immune reset. This is early-stage, single-center, five-patient efficacy data, so it is proof of concept rather than a registrational readout; the commercial case still rests on the SPS and gMG programs. The RMAT designation in non-active secondary progressive MS gives Kyverna a regulatory path, and management says a development strategy update is coming by early 2027. With the stock near its 52-week low, this adds clinical credibility to the neuroimmunology franchise but does not change near-term cash or timeline.
At the time of this announcement, KYTX was trading at $5.43 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $335.8M. The 52-week trading range was $5.40 to $13.67. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.